Development of Respimat® soft mist™ inhaler and its clinical utility in respiratory disorders

Medical Devices: Evidence and Research

Volumn 4, Issue 1, 2011, Pages

  Dalby, Richard N ^a   Eicher, Joachim ^b   Zierenberg, Bernd ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Aerosol; Deposition; Drug delivery; Inhaler device

Indexed keywords

AEROSOLS; ATOMIZERS; DEPOSITION; DRUG DELIVERY; TARGETED DRUG DELIVERY;

BOEHRINGER INGELHEIM; FINE PARTICLE FRACTIONS; INHALER DEVICE; OBSTRUCTIVE LUNG DISEASE; PATIENT SATISFACTION; PRESSURIZED-METERED DOSE INHALERS; RESPIRATORY DISORDERS; TECHNICAL PROPERTIES;

CONTROLLED DRUG DELIVERY;

BRONCHODILATING AGENT; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUNISOLIDE;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; EQUIPMENT DESIGN; HEALTH CARE UTILIZATION; HUMAN; INHALER; MARKETING; METERED DOSE INHALER; PATIENT PREFERENCE; PATIENT SAFETY; PATIENT SATISFACTION; POWDER INHALER; PROCESS DEVELOPMENT; RELIABILITY; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 84930472186     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S7409     Document Type: Review

References (31)

1. Smith G, Hiller C, Mazumder R, Bone R. Aerodynamic size distribution of cromolyn sodium at ambient and airway humidity. Am Rev Respir Dis. 1980;121:513-517.
2. Köhler D, Fleischer W, Matthys H. New method for easy labeling of beta-2-agonists in the metered dose inhaler with technetium 99 m. Respiration. 1988;53:65-73.
3. Newman S P, Pavia D, Clarke S W. How should a pressurized beta-adrenergic bronchodilator be inhaled? Eur J Respir Dis. 1981;62:3-21.
4. Crompton EK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982;119:101-104.
5. Pedersen S, Ostergaard PA. Nasal inhalation as a cause of ineffcient pulmonal aerosol inhalation technique in children. Allergy. 1983;38: 191-194.
6. Handbook for the Montreal Protocol on Substances that Deplete the Ozone Layer. 7th ed. 2006. Available from: http://ozone.unep.org/Pub-lications/MP_Handbook/index.shtml. Accessed May 2, 2011.
7. Meakin BJ, Ganderton D, Panza I, Ventura P. The effect of fow rate on drug delivery from the Pulvinal, a high-resistance dry powder inhaler. J Aerosol Med. 1988;11:143-152.
8. Ganderton D. General factors infuencing drug delivery to the lung. Respir Med. 1997;91 Suppl A:13-16.
9. Ganderton D. Targeted delivery of inhaled drugs: Current challenges and future goals. J Aerosol Med. 1999;12 Suppl 1:3-8.
10. De Young LR, Chambers I, Narayan S, Wu C. The aerodose multidose inhaler device design and delivery characteristics. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory Drug Delivery VI. Buffalo Grove, IL: Interpharm Press; 1998.
11. Schuster J, Rubsamen R, Lloyd P, Lloyd J. The AERx aerosol delivery system. Pharm Res. 1997;14:354-357.
12. Zimlich WC, Ding JY, Busick DR, et al. The development of a novel electrohydrodynamic pulmonary drug delivery device. In: Dalby RN, Byron PR, Farr SJ, Peart J, editors. Respiratory Drug Delivery VII. Raleigh, NC: Seratec Press; 2000.
13. ®. J Aerosol Med. 1999;12:19-24.
14. ® soft mist inhaler (SMI) cartridges after use in COPD patients. J Aerosol Med. 2001;14:385P1-385P3.
15. ™ Inhaler. Int J Pharm. 2004;283:1-9.
16. ®, a novel soft mist inhaler. Respiration. 2000;67:672-678.
17. Steed KP, Freund B, Towse L, Newman S P. High lung deposition of fenoterol from BINEB, a novel multiple dose nebuliser device [Abstract]. Eur Respir J. 1995;8 Suppl 19:204.
18. ™ Inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273-282.
19. Zhang Z, Kleinstreuer C, Kim CS. Micro-particle transport and deposition in a human oral airway model. J Aerosol Sci. 2002;33: 1635-1652.
20. Newman S P, Steed K P, Reader SJ, Hooper G, Zierenberg B. Effcient delivery to the lungs of funisolide aerosol from a new portable handheld multidose nebulizer. J Pharm Sci. 1996;85:960-964.
21. Newman S P, Brown J, Steed K P, Reader SJ, Kladders H. Lung deposition of fenoterol and funisolide delivered using a novel device for inhaled medicines. Chest. 1998;113:957-963.
22. ® dry powder inhaler. J Aerosol Med. 2005;18:264-272.
23. ® compared with a conventional metered dose inhaler. Eur Respir J. 2001;17: 225-232.
24. ® Soft Mist Inhaler (SMI) versus a pressurised metered-dose inhaler in asthma. Clin Drug Invest. 2004;24:17-28.
25. ® Soft Mist Inhaler vs a conventional metered dose inhaler plus spacer in children with asthma. Pediatr Pulmonol. 2004;37:264-272.
26. ® Soft Mist Inhaler in patients with COPD. Respir Med. 2004;98:387-397.
27. ® Soft Mist Inhaler than HFA-MDI in COPD patients with poor technique. Int J COPD. 2008; 3:1-8.
28. Anderson P. Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14:109-116.
29. Kozma CM, Slaton TL, Monz BU, Hodder R, Reese PR. Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med. 2005;4:41-52.
30. ® Soft Mist Inhaler versus hydrofuoroalkane metered dose inhaler: Patient preference and satisfaction. Treat Respir Med. 2005;4: 53-61.
31. ®. Int J Chron Obstruct Pulmon Dis. 2009;4:225-232.